Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial"

Transcription

1 Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich W. Mohr, Haiyan Li, Yang Lei, Kaijun Wang, Kate Robertus, Elizabeth M. Mahoney, Yueping Zhu, Keith D. Dawkins, A. Pieter Kappetein on behalf of the SYNTAX Investigators Saint Luke s Mid America Heart Institute University of Missouri-Kansas City Kansas City, Missouri

2 Disclosures SYNTAX was funded by a research grant from Boston Scientific, Inc. SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 2

3 Background Recently 1-year results from the SYNTAX trial have demonstrated that for patients with left main and/or 3-vessel disease, CABG results in lower rates of MACCE than PCI with DES - driven by a significant reduction in the need for repeat revascularization Since there were no overall differences in irreversible endpoints, however, quality of life and economic factors should be important considerations in determining the optimal treatment for these highly prevalent conditions To address these issues, both quality of life and health economic analyses were included in the design of the SYNTAX trial SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 3

4 Methods: Quality of Life Instrument Seattle Angina Questionnaire (SAQ) SF-36 EQ-5D (EuroQOL) Description/Role CAD-specific QOL Domains: Angina Frequency, Physical Limitations, Disease Perception/QOL Scores: (higher = better) General physical and mental health Scores: (higher = better) Generic instrument for assessment of utilities and QALYs Scores: 0-1 (0=death; 1=perfect health) Assessments performed by self-administered questionnaires at baseline, 1, 6, and 12 months Primary endpoint: SAQ-Angina Frequency Scale SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 4

5 Cost-Effectiveness Analysis Analytic Perspective US healthcare system Patient Population All patients with complete 1 yr follow-up, regardless of country of origin General approach Multiply counts of resources derived from trial population by price weights derived from a comparable US population SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 5

6 Costing Methods: Revascularization Procedures/Hospitalizations Cath lab and OR costs based on measured resource utilization (procedure duration, balloons, stents, wires, etc.) and current unit costs Drug-eluting stent cost =$2000/stent Ancillary hospital costs based on event-based (rather than resource-based) regression models of SYNTAXeligible U.S. patients using 2006 MedPAR data Avoids distortions due to marked differences in LOS across different health care systems Costs also included for-- other CV and non-cv hospitalizations, MD fees, outpatient CV care/testing, cardiac rehabilitation, and outpatient medications SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 6

7 Economic Analysis Plan Primary Endpoints Total 1-year medical care costs Incremental Cost-Effectiveness Ratio ($/QALY gained) Secondary Endpoints Individual components of cost Disease-specific C/E ratios ($/repeat revascularization avoided, $/death, MI, or stroke avoided) Prespecified Subgroups Left main vs. 3-vessel disease Diabetes SYNTAX score tertiles SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 7

8 Baseline QOL PCI (n=837) CABG (n=802) SAQ Angina Frequency 70±26 69±27 Daily (0-30) 11.7% 11.6% Weekly (40-60) 26.2% 27.9% Monthly (70-90) 39.9% 38.4% None (100) 22.2% 22.1% SAQ QOL 46±23 45±23 SF-36 PCS 40±10 40±10 SF-36 MCS 45±12 45±12 EQ-5D Utility 0.75± ±0.19 SYNTAX Health Economics/Quality of Life P=NS for all comparisons ACC 2009 Orlando, FL 8

9 Primary QOL Endpoint: SAQ-Angina Frequency PCI CABG Δ = +1.3 P=0.17 Δ = -1.7 P=0.04 Δ = -1.7 P= Baseline 1 month 6 months 12 months SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 9

10 SAQ-AF: Substantial Improvement* 80% PCI CABG P = NS for all timepoints 60% 54.7% 52.4% 56.5% 57.4% 57.6% 58.3% 40% 20% 0% 1 month 6 months 12 months * Defined as improvement 20 points vs. baseline SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 10

11 SAQ-AF: Angina-Free* 100% PCI CABG P= % 60% P=NS 64.4% 61.6% P=NS 72.0% 68.5% 71.6% 76.3% 40% 20% 0% 1 month 6 months 12 months * Defined as SAQ-AF score = 100 SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 11

12 Generic QOL and Utilities 55 SF-36 Physical Component Summary SF-36 Mental Component Summary P<0.001 P=0.50 P=0.07 P<0.001 P=0.23 P= Baseline 1 month 6 months 12 months 30 Baseline 1 month 6 months 12 months PCI 1 EQ-5D Utilities (US) CABG P<0.001 P=0.16 P= Baseline 1 month 6 months 12 months SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 12

13 Initial Hospitalization Costs Physician Fees Room + Ancillary Repeat Procedures Index Procedure $50,000 $40,000 $30,000 Δ=$5693 (p<0.001) $33,254 $27,560 $20,000 $10,909 $20,536 Revascularized Population $10,000 $0 $14,318 PCI $8,108 CABG SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 13

14 Follow-up Costs $6,000 Δ=$1502 Total F/U Costs PCI CABG $4,000 4,457 PCI $8425 CABG $6144 Δ = $2282 p< ,954 Δ=$1247 $2,000 Δ=$368 Δ=($834) 2,253 $0 1,051 1,499 1, Hospitalizations MD fees Rehab Services 1,006 Outpatient Medications SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 14

15 Total 1-Year Costs 1-Year Follow-up Initial Hospitalization $60,000 $50,000 $40,000 Δ=$3590 (P<0.001) $39,581 $35,991 $30,000 $20,000 $10,000 $0 PCI CABG SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 15

16 Cost-Effectiveness of CABG vs. PCI* Overall Population $10,000 $5,000 Cost QALYs CABG Dominated Δ cost = $3590 Δ effect = QALYs Δ 1-yr cost (CABG-PCI) $0 -$5,000 $50,000 per QALY *$/QALY Cost QALYs -$10, Δ Quality Adjusted Life-Years (CABG-PCI) Cost QALYs SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 16

17 Subgroup Analysis: SYNTAX Score Tertiles $50,000 Total 1-Year Cost Δ=$6154 Δ=$3889 Δ=$467 $40,000 $30,000 $32,292 $38,446 $36,084 $39,973 $39,765 $40,232 $20,000 $10,000 P = for interaction $0 Low ( 22) Middle High ( 33) PCI CABG SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 17

18 Cost-Effectiveness of CABG vs. PCI ($/QALY) SYNTAX Score Tertiles Low ( 22) Mid (23-32) High ( 33) $10,000 $7,500 $5,000 $2,500 $0 -$2, Δ Cost $6154 Δ Cost $3889 Δ Cost $467 Δ QALY Δ QALY Δ QALY ICER Dominated ICER Dominated ICER $43,000/QALY Pr <$50K/QALY = 0.0% Pr <$50K/QALY = 0.3% Pr <$50K/QALY = 49% SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 18

19 Limitations Analysis performed from a US perspective results likely to differ in other healthcare systems because of differences in patterns of resource use and costs DES cost: US- $2000 UK- $1200 GER- $800 Hosp. day: US- $1500 UK- $400 GER- $320 1-year time horizon does not fully capture differences in long-term survival and QOL 5 yr economic and QOL analyses planned SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 19

20 Summary: QOL Among patients undergoing revascularization for left main or 3-vessel CAD, angina relief was slightly better with CABG than DES at 6 and 12 months. The magnitude of benefit was smaller than in previous CABG vs. PCI comparisons, however, and below the threshold that most patients would find clinically meaningful All other QOL endpoints favored PCI at 1 month, although these differences were transient and largely resolved by 6 months SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 20

21 Summary: Cost-Effectiveness Despite substantially higher procedural costs for PCI, initial treatment costs were ~$6000/pt higher with CABG mainly due to differences in LOS, complications, and physician costs Follow-up costs were ~$2500/pt lower with CABG, driven largely by differences in the need for additional revascularization procedures and lower medication costs Although total 1-year costs remained significantly lower with PCI, the overall cost-effectiveness of PCI vs. CABG differed substantially according to pt characteristics- particularly angiographic complexity SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 21

22 Summary: Cost-Effectiveness (2) SYNTAX Score Net Cost of PCI 1-Yr Cost-Effectiveness Low (0-22) 20% PCI dominant Med (23-32) 8% PCI dominant High ( 33) Neutral CABG economically attractive Longer-term follow-up is essential (and planned) to fully assess both QOL and costeffectiveness for these challenging populations SYNTAX Health Economics/Quality of Life ACC 2009 Orlando, FL 22

23

PCI vs. CABG for Left Main Disease

PCI vs. CABG for Left Main Disease The EXCEL Ti Trial Design, Status, t and Timelines Gregg W. Stone, MD Columbia University Medical Center NewYork-Presbyterian Hospital Cardiovascular Research Foundation PCI vs. CABG for Left Main Disease

More information

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf

More information

The Use of a Probabilistic Sensitivity Analysis for Decision Making: The example of Drug- Eluting Stents

The Use of a Probabilistic Sensitivity Analysis for Decision Making: The example of Drug- Eluting Stents The Use of a Probabilistic Sensitivity Analysis for Decision Making: The example of Drug- Eluting Stents Mark Sculpher, PhD Professor Centre for Health Economics University of York, UK Seminar at Harvard

More information

LEADERS: 5-Year Follow-up

LEADERS: 5-Year Follow-up LEADERS: -Year Follow-up from a Prospective, Randomized Trial of Biolimus A9-eluting Stents with a Biodegradable Polymer vs. Sirolimus-eluting Stents with a Durable Polymer : Final Report of the LEADERS

More information

The ACC 50 th Annual Scientific Session

The ACC 50 th Annual Scientific Session Special Report The ACC 50 th Annual Scientific Session Part Two From March 18 to 21, 2001, physicians from around the world gathered to learn, to teach and to discuss at the American College of Cardiology

More information

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada April 2009 Jack V. Tu, MD PhD FRCPC CANADA RESEARCH CHAIR IN HEALTH SERVICES RESEARCH Institute

More information

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient? --- NIRS-IVUS TVC Imaging Adds Additional Information for the Heart Team Dr. Luis Tami Memorial Regional Hospital

More information

Marina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC

Marina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC Assessing the Impact of Southwestern Ontario s Community Stroke Rehabilitation Teams: An Economic Analysis Presenters: Laura Allen, M.Sc. (cand.) Matthew Meyer, Ph.D (cand.) Marina Richardson, M.Sc. Deb

More information

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-elevation myocardial infarction 3 year follow-up of the randomised trial Peter Clemmensen, Henning Kelbæk,

More information

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Background 8 th Coronary Physiology in the CathLab Course Revascularisation of intermediate stenosis can be targeted EITHER

More information

IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice

IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice IC 3 : Improving Continuous Cardiac Care Quality Improvement in Practice Presenter Disclosure Information Paul Chan, MD FINANCIAL DISCLOSURE: None FUNDING FOR THE IC3 PROGRAM: Bristol-Myers Squibb / Sanofi

More information

European Health Economic Trial on Home Monitoring in ICD Patients

European Health Economic Trial on Home Monitoring in ICD Patients European Health Economic Trial on Home Monitoring in ICD Patients www.clinicaltrials.gov NCT00776087 Fast-Track publication in European Heart Journal Prof. Dr. Hein Heidbuchel Hasselt University & Heart

More information

Antonio Colombo MD on behalf of the SECURITY Investigators

Antonio Colombo MD on behalf of the SECURITY Investigators Second Generation Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy - The SECURITY Randomized Clinical Trial Antonio Colombo MD on behalf of the SECURITY

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Majestic Trial 12 Month Results

Majestic Trial 12 Month Results Majestic Trial 12 Month Results S.Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA ACADEMIC HOSPITALS Flensburg of Kiel University Ev.-Luth. Diakonissenanstalt zu Flensburg Knuthstraße 1, 24939 FLENSBURG Dept.

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

A Comprehensive Strategy for Coordinating the Care for Patients with Coronary Artery Disease (CAD) and Other Chronic Medical Conditions

A Comprehensive Strategy for Coordinating the Care for Patients with Coronary Artery Disease (CAD) and Other Chronic Medical Conditions A Comprehensive Strategy for Coordinating the Care for Patients with Coronary Artery Disease (CAD) and Other Chronic Medical Conditions Presented at the Integrated Healthcare Association Meeting Los Angeles,

More information

06 Validation of risk prediction model

06 Validation of risk prediction model HA Territory-wide PCI Audit 2003-06 06 Validation of risk prediction model PCI Audit Working Group Central Committee (Cardiac Services) HA Convention 2007 Background Participants: All HA hospitals via

More information

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen

More information

NICE s Appraisal of Cancer Medications: Recent Policy and Methodological Challenges

NICE s Appraisal of Cancer Medications: Recent Policy and Methodological Challenges NICE s Appraisal of Cancer Medications: Recent Policy and Methodological Challenges Mark Sculpher, PhD Professor of Health Economics Centre of Health Economics University of York, UK Fred Hutchinson Cancer

More information

Pooled RESOLUTE Clinical Program

Pooled RESOLUTE Clinical Program The Relationship Between Short and Long-term Antiplatelet Therapy Use and Stent Thrombosis Following Percutaneous Coronary Intervention With the Resolute Zotarolimus-eluting Stent Pooled RESOLUTE Clinical

More information

Treatment of Diabetic Patient with Multivessel Coronary Artery Disease: the Surgeon Perspective

Treatment of Diabetic Patient with Multivessel Coronary Artery Disease: the Surgeon Perspective Treatment of Diabetic Patient with Multivessel Coronary Artery Disease: the Surgeon Perspective Fabio B. Jatene Full Professor of Cardiovascular Surgery Heart Institute - HC-FMUSP fabiojatene@incor.usp.br

More information

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013

Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation. Michael Acker, MD For the CTSN Investigators AHA November 2013 Mitral Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation Michael Acker, MD For the CTSN Investigators AHA November 2013 Acknowledgements Supported by U01 HL088942 Cardiothoracic

More information

Cardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility?

Cardiac Rehab. Home. www.homecareforyou.com. Do you suffer from a cardiac condition that is limiting your independence in household mobility? TM Nightingale Home Cardiac Rehab Do you suffer from a cardiac condition that is limiting your independence in household mobility? Such as, 1. A recent heart attack 2. A heart condition coronary artery

More information

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical

More information

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Duration of Dual Antiplatelet Therapy After Coronary Stenting Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are

More information

Disclosures Funded by VHA HSR&D Investigator Initiated Award (IIR ) Dr. Bosworth was supported by a VHA HSR&D Senior Scientist Award (08-027) Dr

Disclosures Funded by VHA HSR&D Investigator Initiated Award (IIR ) Dr. Bosworth was supported by a VHA HSR&D Senior Scientist Award (08-027) Dr Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge Ho PM, Lambert-Kerzner A, Carey EP, Fahdi

More information

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the

BRIGHT Trial. Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI. Thirty-Day and One-Year Outcomes of the Bivalirudin versus Heparin and Heparin plus Tirofiban in Patients with AMI Undergoing PCI Thirty-Day and One-Year Outcomes of the BRIGHT Trial Yaling Han, MD, FACC On behalf of the BRIGHT investigators

More information

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial

University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial Seung-Jung Park MD PhD Seung-Jung Park, MD, PhD, University of Ulsan

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Description of problem Description of proposed amendment Justification for amendment ERG response

Description of problem Description of proposed amendment Justification for amendment ERG response KEY INACCURACIES Issue 1 Distinguishing between groups of STEMI patients Key issue throughout the report The ERG distinguishes between groups of STEMI patients defining four patient groups: STEMI without

More information

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center

Appropriate Use: Big Brother is Watching. Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Appropriate Use: Big Brother is Watching Jason H. Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Disclosures Consultant Boston Scientific, Medtronic, Middle Peak Medical, Millipede,

More information

An overview of the methods of economic evaluation in health care

An overview of the methods of economic evaluation in health care 2013 Vol.62 No.6 p.584 589 An overview of the methods of economic evaluation in health care Takashi FUKUDA Center for Public Health Informatics, National Institute of Public Health Incremental Cost Effectiveness

More information

on behalf of the AUGMENT-HF Investigators

on behalf of the AUGMENT-HF Investigators One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas

More information

No conflict of interest

No conflict of interest Anthony Fung Presenter Disclosure The BRIEF-PCI Trial No conflict of interest Brief Infusion of Eptifibatide Following PCI The BRIEF-PCI Trial AY Fung, J Saw, A Starovoytov, C Densem, P Jokhi, SJ Walsh,

More information

Benefit Design and ACOs: How Will Private Employers and Health Plans Proceed?

Benefit Design and ACOs: How Will Private Employers and Health Plans Proceed? Benefit Design and ACOs: How Will Private Employers and Health Plans Proceed? Accountable Care Organizations: Implications for Consumers October 14, 2010 Washington, DC Sam Nussbaum, M.D. Executive Vice

More information

THE SECRETS OF OUR SUCCESS

THE SECRETS OF OUR SUCCESS THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?

More information

Performance Measures for. What? When? How?

Performance Measures for. What? When? How? Performance Measures for Cardiac and Pulmonary Rehabilitation: What? When? How? 5th Cardiopulmonary Rehabilitation Workshop 2011- Webinar Seoul, Korea Friday, April 29, 2011 Randal J. Thomas, MD, MS, FAACVPR,

More information

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Stent for Life Initiative How can we improve system delay and patients delay in STEMI Stent for Life Initiative How can we improve system delay and patients delay in STEMI Z. Kaifoszova SFL Initiative Europe 2011 Stent for Life Initiative 10 countries participate in the program Declaration

More information

Cardiac Rehabilitation

Cardiac Rehabilitation Cardiac Rehabilitation Cardiac Rehabilitation Most patients return to usual activities within a few months after a heart attack and/or surgery. Cardiac rehabilitation (rehab) monitors and assists you

More information

Remote Delivery of Cardiac Rehabilitation

Remote Delivery of Cardiac Rehabilitation Remote Delivery of Cardiac Rehabilitation Bonnie Wakefield, RN, PhD Kariann Drwal, MS Melody Scherubel, RN Thomas Klobucar, PhD Skyler Johnson, MS Peter Kaboli, MD, MS VA Rural Health Resource Center Central

More information

FFR in the diagnostic phase

FFR in the diagnostic phase FFR in the diagnostic phase Nick Curzen BM(Hons) PHD FRCP Professor of Interventional Cardiology Southampton, UK Conflicts of Interest Unrestricted research funding from: St Jude Medical; Medtronic; Boston

More information

Analytics. HealthView. Cardiovascular Information Systems. www.lumedx.com sales@lumedx.com

Analytics. HealthView. Cardiovascular Information Systems. www.lumedx.com sales@lumedx.com HealthView Analytics www.lumedx.com sales@lumedx.com Cardiovascular Information Systems 555 Twelfth Street, Suite 2060, Oakland, CA 94607 Tel 800.966.0699 Fax 510.419.3699 Meaningful Data for Clinical

More information

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo Acute Coronary Syndromes: oral antithrombotic therapy Focus on

More information

Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과

Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과 Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation

More information

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary

More information

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease What is Cardiac Rehabilitation? Cardiac rehabilitation is a comprehensive exercise, education, and behavior modification

More information

DEVICE RECALLS: The Era of Regulation and Outcome Metrics: Optimizing Benefits and Managing Risks

DEVICE RECALLS: The Era of Regulation and Outcome Metrics: Optimizing Benefits and Managing Risks DEVICE RECALLS: The Era of Regulation and Outcome Metrics: Optimizing Benefits and Managing Risks Kenneth A. Ellenbogen, MD Kontos Professor & Chairman Virginia Commonwealth University School of Medicine

More information

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators

PIHRATE Trial. Polish-Italian-Hungarian Randomized ThrombEctomy Trial. Dariusz Dudek MD, PhD. On behalf PIHRATE investigators Polish-Italian-Hungarian Randomized ThrombEctomy Trial PIHRATE Trial On behalf PIHRATE investigators Dariusz Dudek MD, PhD Institute of Cardiology, Krakow, Poland Impact of distal embolization Distal embolization

More information

EMR Tutorial Acute Coronary Syndrome

EMR Tutorial Acute Coronary Syndrome EMR Tutorial Acute Coronary Syndrome How to find the Acute Coronary Syndrome AAA Home Page 1 of 26 Master Tool Bar Icon When the Template button is clicked you will be presented with the preference list.

More information

The clinical effectiveness and costeffectiveness surgery for obesity: a systematic review and economic evaluation

The clinical effectiveness and costeffectiveness surgery for obesity: a systematic review and economic evaluation The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity The clinical effectiveness and costeffectiveness of bariatric (weight loss) surgery for obesity: a systematic

More information

What is meant by "randomization"? (Select the one best answer.)

What is meant by randomization? (Select the one best answer.) Preview: Post-class quiz 5 - Clinical Trials Question 1 What is meant by "randomization"? (Select the one best answer.) Question 2 A. Selection of subjects at random. B. Randomization is a method of allocating

More information

Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks

Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks Intermittent Androgen Deprivation Therapy (ADT): Benefits outweigh risks Laurence Klotz Professor of Surgery Sunnybrook Health Sciences Centre University of Toronto Advantages of intermittent ADT Likely:

More information

FFR CT : Clinical studies

FFR CT : Clinical studies FFR CT : Clinical studies Bjarne Nørgaard Department Cardiology B Aarhus University Hospital Skejby, Denmark Disclosures: Research grants: Edwards and Siemens Coronary CTA: High diagnostic sensitivity

More information

Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter

Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme der V. saphena in der koronaren Bypasschirurgie - Aktuelle Datenlage - Dr. med. Stefanie Reutter Endoskopische Venenentnahme (EVH) - Einführung 1979 Tevaearai und Kollegen haben

More information

DDD is Superior to VVI?

DDD is Superior to VVI? DDD is Superior to VVI? Jeong-Gwan Cho, MD, FACC Division of Cardiology Chonnam University Hospital What is your answer? My answer is no, based on the several randomized clinical trials. The era of evidence-based

More information

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators)

EXAMINATION trial. Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Manel Sabaté Hospital Clínic, Barcelona (On behalf of the Examination Investigators) EXAMINATION trial Background and Rationale (I) Acute coronary syndromes repeatedly appear as independent

More information

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial)

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation (ISAR-TRIPLE Trial) Katrin A. Fiedler, Michael Maeng, Julinda Mehilli, Stefanie Schulz, Robert

More information

Cardiac Rehab and Primary Care: Avoiding Losses in Care Transitions. Neville Suskin Heart & Stroke Clinical Update 2012

Cardiac Rehab and Primary Care: Avoiding Losses in Care Transitions. Neville Suskin Heart & Stroke Clinical Update 2012 Cardiac Rehab and Primary Care: Avoiding Losses in Care Transitions Neville Suskin Heart & Stroke Clinical Update 2012 1 Disclosure Med. Director SJHC CR Co-principal of Lawson e-cr application LCVIS SJHC

More information

rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc.

rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. rivaroxaban 2.5mg film-coated tablets (Xarelto ) SMC No. (1062/15) Bayer plc. 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

EARLY ECONOMIC MODELS PAY OFF IN PRODUCT DEVELOPMENT

EARLY ECONOMIC MODELS PAY OFF IN PRODUCT DEVELOPMENT AN ARTICLE FROM PAREXEL ACCESS EARLY ECONOMIC MODELS PAY OFF IN PRODUCT DEVELOPMENT Once drug developers have achieved regulatory approval with data from trials against the standard of care, they must

More information

Databases in Clinical Research. Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support

Databases in Clinical Research. Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support Databases in Clinical Research Harvard-MIT Division of Health Sciences and Technology HST.951J: Medical Decision Support Overview Background: History and utility of clinical data repositories Strategies:

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease

More information

Postoperative Myocardial Infarction: Diagnosis and Management

Postoperative Myocardial Infarction: Diagnosis and Management Postoperative Myocardial Infarction: Diagnosis and Management Todd M. Brown, MD, MSPH Chief Fellow Division of Cardiovascular Diseases December 9, 2008 CHEST PAIN NON-ANGINAL UNSURE ANGINAL STABLE ANGINA

More information

Intensive Cardiac Rehabilitation: Value Creation in Today's FFS World and Reducing Medical Spending in a Value Based Environment

Intensive Cardiac Rehabilitation: Value Creation in Today's FFS World and Reducing Medical Spending in a Value Based Environment Intensive Cardiac Rehabilitation: Value Creation in Today's FFS World and Reducing Medical Spending in a Value Based Environment Terri Merritt-Worden, MS, FAACVPR Vice President- Partnership Operations

More information

An Assessment of the Cost-Utility of Therapy for Psoriasis

An Assessment of the Cost-Utility of Therapy for Psoriasis An Assessment of the Cost-Utility of Therapy for Psoriasis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published

More information

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators

Steven J. Yakubov, MD FACC For the CoreValve US Clinical Investigators Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From the CoreValve US Pivotal Trial Steven J. Yakubov,

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Peripheral Vascular Disease:!! Burden In Saudi Arabia. Owayed Al Shammeri, MD Qassim University Prince Sultan Cardiac Center in Qassim

Peripheral Vascular Disease:!! Burden In Saudi Arabia. Owayed Al Shammeri, MD Qassim University Prince Sultan Cardiac Center in Qassim Peripheral Vascular Disease:!! Burden In Saudi Arabia Owayed Al Shammeri, MD Qassim University Prince Sultan Cardiac Center in Qassim Introduction All individuals with PVD, regardless of limb symptoms,

More information

Primary Prevention of Cardiovascular Disease with a Mediterranean diet

Primary Prevention of Cardiovascular Disease with a Mediterranean diet Primary Prevention of Cardiovascular Disease with a Mediterranean diet Alejandro Vicente Carrillo, Brynja Ingadottir, Anne Fältström, Evelyn Lundin, Micaela Tjäderborn GROUP 2 Background The traditional

More information

Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease in Korea

Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease in Korea ORIGINAL ARTICLE Medicine General & Social Medicine DOI: 10.3346/jkms.2010.25.9.1259 J Korean Med Sci 2010; 25: 1259-1271 Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma,

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke

More information

Heart information. Coronary angioplasty and stents

Heart information. Coronary angioplasty and stents Heart information Coronary angioplasty and stents Contents 2 What is coronary angioplasty? 2 Coronary angioplasty is not a cure 3 Why do I need coronary angioplasty? 4 What will happen before I have coronary

More information

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest

More information

Cost-effectiveness of Fidaxomicin (Dificlir ) tablets for the treatment of adults with Clostridium difficileassociated

Cost-effectiveness of Fidaxomicin (Dificlir ) tablets for the treatment of adults with Clostridium difficileassociated Cost-effectiveness of Fidaxomicin (Dificlir ) tablets for the treatment of adults with Clostridium difficileassociated diarrhoea. February 2013 1. Fidaxomicin is indicated in adults for the treatment of

More information

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care

Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Impact of Massachusetts Health Care Reform on Racial, Ethnic and Socioeconomic Disparities in Cardiovascular Care Michelle A. Albert MD MPH Treacy S. Silbaugh B.S, John Z. Ayanian MD MPP, Ann Lovett RN

More information

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa 1999. Objectives. No disclosures, no conflicts Cardiac Rehabilitation: From the other side of the glass door No disclosures, no conflicts Charles X. Kim, MD, FACC, ABVM Objectives 1. Illustrate common CV benefits of CV rehab in real world practice.

More information

Utilizing the Cath Lab for Cardiac Arrest

Utilizing the Cath Lab for Cardiac Arrest Utilizing the Cath Lab for Cardiac Arrest Khaled M. Ziada, MD Director, Cardiovascular Catheterization Laboratories Gill Heart Institute, University of Kentucky UK/AHA Strive to Revive Symposium May 2013

More information

Evaluating the Effectiveness of Physician and Clinical Pharmacist Patient Education and Disease Management in Diabetes Mellitus

Evaluating the Effectiveness of Physician and Clinical Pharmacist Patient Education and Disease Management in Diabetes Mellitus Evaluating the Effectiveness of Physician and Clinical Pharmacist Patient Education and Disease Management in Diabetes Mellitus Sotheavy Vann Jackson-Hinds Comprehensive Health Center Jackson, MS Introduction

More information

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

MEDICAL POLICY No. 91580-R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE Effective Date: October 1, 2015 Review Dates: 10/11, 10/12, 10/13, 8/14, 8/15 Date Of Origin: October 12, 2011 Status: Current Summary of Changes Clarifications:

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy

Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Perspectives on the Selection and Duration of Dual Antiplatelet Therapy Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University

More information

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program Jean Fajadet, MD, FESC Clinique Pasteur - Toulouse - France Disclosure statement Nothing to disclose Dedicated Delivery

More information

Comparative Tolerability and Harms of Individual Statins

Comparative Tolerability and Harms of Individual Statins Comparative Tolerability and Harms of Individual Statins J.J.Brugts MD PhD MSc(1); H. Naci PhD MHS(2); T. Ades PhD(2) (1) Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands (2) London School

More information

Clinical characteristics & impact of Peripheral Vascular Disease in Diabetes. Keimyung University Hye Soon Kim

Clinical characteristics & impact of Peripheral Vascular Disease in Diabetes. Keimyung University Hye Soon Kim Clinical characteristics & impact of Peripheral Vascular Disease in Diabetes Keimyung University Hye Soon Kim Peripheral Vascular Disease Diseases to arteries & veins outside thoracic region Main cause

More information

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada, Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis in Limus- Eluting Stents Intracoronary Stenting

More information

The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx:

The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: James Cromie The Arguments: T2DM - tremendous economic burden globally Lifestyle / Pharm Rx: INEFFECTIVE and UNSUSTAINED Bariatric surgery is an Effective and Durable treatment option Well established

More information

Health Economics. The Basics. Pat Berrigan Fall 2015

Health Economics. The Basics. Pat Berrigan Fall 2015 Health Economics The Basics Pat Berrigan Fall 2015 1 Topics 1) What is heath economics and why do we do it; 2) Types of health economic analyses; 3) Cost-effectiveness analysis; 4) The incremental cost-effectiveness

More information

Critical Issues in Managing Critical Illness Insurance. Date: March 18 & 19, 2002

Critical Issues in Managing Critical Illness Insurance. Date: March 18 & 19, 2002 Critical Issues in Managing Critical Illness Insurance Date: March 18 & 19, 2002 Critical Illness - A Brief Overview A Typical Critical Illness Policy $ Lump Sum if Cancer Heart Attack Stroke Kidney Failure

More information

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)

UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) Pilot QOF indicator: The percentage of patients 79

More information

EMR Effectiveness: The Positive Benefit Electronic Medical Record Adoption has on Mortality Rates

EMR Effectiveness: The Positive Benefit Electronic Medical Record Adoption has on Mortality Rates EMR Effectiveness: The Positive Benefit Electronic Medical Record Adoption has on Mortality Rates With clinical data and analytics support provided by Healthgrades 2 Executive Summary Given the billions

More information

Renovascular Hypertension

Renovascular Hypertension Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension

More information

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.

More information

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands Comparing zotarolimus-eluting and bare-metal stent efficacy in selected high bleeding risk patients treated with a short dual antiplatelet therapy duration. A pre-specified analysis from the The Zotarolimuseluting

More information

FFR and Acute Coronary Syndromes. William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center

FFR and Acute Coronary Syndromes. William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center FFR and Acute Coronary Syndromes William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Disclosure Statement of Financial Interest Within the past

More information

How valuable is a cancer therapy? It depends on who you ask.

How valuable is a cancer therapy? It depends on who you ask. How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr

More information